PMID- 38130400
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231223
IS  - 2633-4690 (Electronic)
IS  - 2633-4682 (Print)
IS  - 2633-4690 (Linking)
VI  - 2023
DP  - 2023
TI  - In Vitro Synergistic Activity of Combinations of Tetrahydroisoquinolines and 
      Treatment Antibiotics against Multidrug-Resistant Salmonella.
PG  - 6142810
LID - 10.1155/2023/6142810 [doi]
LID - 6142810
AB  - The global burden of Salmonella infections remains high due to the emergence of 
      multidrug resistance to all recommended treatment antibiotics. 
      Tetrahydroisoquinolines (THIQs) have demonstrated promising activity against 
      multidrug-resistant (MDR) Salmonella Typhi. Hence, their interaction with 
      treatment antibiotics was investigated for possible synergy. Twenty combinations 
      of five THIQs (1, 2, 3, 4, and 5) and four antibiotics were tested against each 
      of 7 Salmonella isolates by the checkerboard method giving a total of 140 assays 
      performed. Fractional inhibitory concentration indices (FICIs) were calculated, 
      and isobolograms were plotted. In terms of FICI, synergism ranged from 0.078 to 
      0.5 and the highest magnitude (0.078) was recorded for chloramphenicol-THIQ 1 
      combination. In a total of 140 antibiotics-THIQs combination assays, 27 were 
      synergistic (17%), 42 were additive (30%), 11 were antagonistic (7.8%), and 60 
      were indifferent (42%). The synergistic activity recorded for each antibiotic 
      class in combination based on the total of 7 bacterial isolates tested ranged 
      from 14.29% to 71.43%; the highest percentage was recorded for two combinations 
      (chloramphenicol or sulphamethoxazole with THIQ 1). Ciprofloxacin-THIQ 1 
      combination showed additivity on all bacteria isolates tested (100%). Overall, 
      THIQ 1 was the most synergistic and most additive in combination with three 
      antibiotics (ampicillin, chloramphenicol, or sulphamethoxazole-trimethoprim). 
      Some combinations of the THIQs and treatment antibiotics have shown high 
      synergism which could potentially be efficacious against multidrug-resistant S. 
      Typhi, hence this interaction should be further studied in vivo.
CI  - Copyright (c) 2023 Rita Ayuk Ndip et al.
FAU - Ndip, Rita Ayuk
AU  - Ndip RA
AD  - Department of Biochemistry and Molecular Biology, University of Buea, P.O. Box 
      63, Buea, Cameroon.
FAU - Hanna, Joelle Ngo
AU  - Hanna JN
AD  - Department of Chemistry, Faculty of Science, University of Douala, P.O. Box 
      24157, Douala, Cameroon.
FAU - Mbah, James Ajeck
AU  - Mbah JA
AD  - Department of Chemistry, Faculty of Science, University of Buea, P.O. Box 63, 
      Buea, Cameroon.
FAU - Ghogomu, Stephen Mbigha
AU  - Ghogomu SM
AD  - Department of Biochemistry and Molecular Biology, University of Buea, P.O. Box 
      63, Buea, Cameroon.
FAU - Ngemenya, Moses Njutain
AU  - Ngemenya MN
AUID- ORCID: 0000-0003-2322-5133
AD  - Department of Biochemistry and Molecular Biology, University of Buea, P.O. Box 
      63, Buea, Cameroon.
AD  - Department of Medical Laboratory Sciences, University of Buea, P.O. Box 63, Buea, 
      Cameroon.
LA  - eng
PT  - Journal Article
DEP - 20231213
PL  - England
TA  - Adv Pharmacol Pharm Sci
JT  - Advances in pharmacological and pharmaceutical sciences
JID - 101762941
PMC - PMC10733592
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2023/12/22 06:42
MHDA- 2023/12/22 06:43
PMCR- 2023/12/13
CRDT- 2023/12/22 03:48
PHST- 2023/04/06 00:00 [received]
PHST- 2023/10/31 00:00 [revised]
PHST- 2023/12/04 00:00 [accepted]
PHST- 2023/12/22 06:43 [medline]
PHST- 2023/12/22 06:42 [pubmed]
PHST- 2023/12/22 03:48 [entrez]
PHST- 2023/12/13 00:00 [pmc-release]
AID - 10.1155/2023/6142810 [doi]
PST - epublish
SO  - Adv Pharmacol Pharm Sci. 2023 Dec 13;2023:6142810. doi: 10.1155/2023/6142810. 
      eCollection 2023.